OPKO Health, Inc. Stock price

Equities

OPK

US68375N1037

Healthcare Facilities & Services

Market Closed - Nasdaq 04:15:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.2 USD +12.15% Intraday chart for OPKO Health, Inc. +34.83% -20.53%
Sales 2024 * 772M Sales 2025 * 847M Capitalization 746M
Net income 2024 * -262M Net income 2025 * -187M EV / Sales 2024 * 0.97 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.88 x
P/E ratio 2024 *
-3.33 x
P/E ratio 2025 *
-4.76 x
Employees 3,930
Yield 2024 *
-
Yield 2025 *
-
Free-Float 46.99%
More Fundamentals * Assessed data
Dynamic Chart
Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets MT
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome CI
Opko Health Insider Bought Shares Worth $444,300, According to a Recent SEC Filing MT
Opko Health Insider Bought Shares Worth $463,750, According to a Recent SEC Filing MT
Opko Health Insider Bought Shares Worth $559,380, According to a Recent SEC Filing MT
Barrington Cuts Price Target on OPKO Health to $1.50 From $2, Maintains Outperform Rating MT
Transcript : OPKO Health, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Earnings Flash (OPK) OPKO HEALTH Reports Q4 Revenue $181.9M, vs. Street Est of $177.5M MT
OPKO Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Drugmakers deepen efforts to tap into booming market for obesity drugs RE
Opko Health Insider Bought Shares Worth $991,700, According to a Recent SEC Filing MT
HealthSnap, Inc. announced that it has received $24.999999 million in funding from a group of investors CI
OPKO Health, Inc. Announces the Cessation of Alexis Borisy as Member of the Board of Directors and Member of Compensation Committee of the Board CI
NextPlat Preparing to Launch Opko Health Store on Alibaba's Tmall Global Platform MT
Opko Health Insider Bought Shares Worth $488,650, According to a Recent SEC Filing MT
More news
1 day+12.15%
1 week+34.83%
Current month+20.00%
1 month+14.29%
3 months-24.05%
6 months-23.08%
Current year-20.53%
More quotes
1 week
0.92
Extreme 0.915
1.25
1 month
0.86
Extreme 0.8601
1.25
Current year
0.85
Extreme 0.8516
1.57
1 year
0.85
Extreme 0.8516
2.24
3 years
0.85
Extreme 0.8516
5.25
5 years
0.85
Extreme 0.8516
6.47
10 years
0.85
Extreme 0.8516
19.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 87 07-03-26
Director of Finance/CFO 46 07-02-28
President 71 22-05-08
Members of the board TitleAgeSince
Chief Executive Officer 87 07-03-26
Director/Board Member 77 20-12-17
Director/Board Member 68 07-12-31
More insiders
Date Price Change Volume
24-03-28 1.209 +12.99% 28,867,498
24-03-27 1.07 +5.94% 11,816,653
24-03-26 1.01 0.00% 3,616,364
24-03-25 1.01 +4.71% 29,847,768
24-03-22 0.9646 +3.72% 25,547,040

Delayed Quote Nasdaq, March 28, 2024 at 04:15 pm EDT

More quotes
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.209 USD
Average target price
4.25 USD
Spread / Average Target
+251.53%
Consensus
  1. Stock
  2. Equities
  3. Stock OPKO Health, Inc. - Nasdaq